Poverty and InequalitySexual and Reproductive HealthFamily, Maternal & Child HealthMethodology

Long noncoding RNA BDNF-AS is associated with clinical outcomes and has functional role in human prostate cancer

TitleLong noncoding RNA BDNF-AS is associated with clinical outcomes and has functional role in human prostate cancer
Publication TypeJournal Article
Year of Publication2018
AuthorsLi, W, Dou, Z, We, S, Zhu, Z, Pan, D, Jia, Z, Liu, H, Wang, X, Yu, G
JournalBiomed Pharmacother
Date PublishedJun
ISBN Number0753-3322
Accession Number29710528
KeywordsAged, Animals, Bdnf-as, Biomarkers, Tumor/metabolism, Cancer proliferation, CaP, Cell Line, Tumor, Cell Proliferation/genetics, Down-Regulation/genetics, Explant, Gene Expression Regulation, Neoplastic, Humans, Invasion, lncRNA, Male, Mice, Nude, Neoplasm Invasiveness, prognosis, Prostatic Neoplasms/*genetics/pathology, RNA, Long Noncoding/*genetics/metabolism, Survival Analysis, Treatment Outcome

BACKGROUND: The underlying molecular mechanisms of prostate cancer (CaP) are largely unknown. We investigated the expression, prognostic value and functional role of long non-coding RNA (lncRNA) brain-derived neurotrophin factor antisense (BDNF-AS) in CaP. METHODS: Clinical tumor samples were excised from patients with CaP. Their endogenous BDNF-AS expression levels were evaluated by qRT-PCR. Correlations between CaP patients' endogenous BDNF-AS expression and their clinicopathological factors, overall survival were statistically analyzed. BDNF-AS expression levels were also probed in immortal CaP cell lines. In LNCaP and PC-3 cells, BDNF-AS was ectopically overexpressed through lentiviral transduction. The functions of BDNF-AS upregulation on CaP cell development were evaluated both in vitro and in vivo. RESULTS: BDNF-AS was downregulated in human CaP tumors. Low BDNF-AS expression was correlated with CaP patients' poor prognosis and shorter overall survival. BDNF-AS was also found to be lowly expressed in CaP cell lines. In LNCaP and PC-3 cells, lentivirus-driven BDNF-AS overexpression exerted significantly tumor-suppressing effects on hindering cancer cell proliferation and invasion in vitro, and explant growth in vivo. CONCLUSION: Downregulated BDNF-AS in CaP patients could be a potential prognostic biomarker for predicating poor prognosis and survival. Upregulating BDNF-AS may be a novel molecular intervening target for CaP treatment.